Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, Merli F, Baldini L, Stelitano C, Partesotti G, Polimeno G, Montanini A, Mammi C, Brugiatelli M. Federico M, et al. Among authors: gobbi pg. Eur J Haematol. 2006 Mar;76(3):217-29. doi: 10.1111/j.1600-0609.2005.00609.x. Eur J Haematol. 2006. PMID: 16451396 Clinical Trial.
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.
Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gianelli U, Maiorana A, Merli F, Bellei M, Pozzi S, Stelitano C, Lazzaro A, Gobbi PG, Baldini L, Bergantini S, Fregoni V, Brugiatelli M. Federico M, et al. Among authors: gobbi pg. Haematologica. 2007 Nov;92(11):1482-8. doi: 10.3324/haematol.11502. Haematologica. 2007. PMID: 18024396 Free article.
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M, et al. Among authors: gobbi pg. J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5. J Clin Oncol. 2009. PMID: 19124807 Clinical Trial.
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M. Iannitto E, et al. Among authors: gobbi pg. Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034. Clin Lymphoma Myeloma. 2009. PMID: 19406724 Clinical Trial.
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M. Mannina D, et al. Among authors: gobbi pg. Leuk Lymphoma. 2010 Mar;51(3):422-9. doi: 10.3109/10428190903518352. Leuk Lymphoma. 2010. PMID: 20038237
168 results